Lexaria Bioscience Corp. LXRP Archives - Page 20 of 27

TuesdayMay 01, 2018 9:28 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Licensing Agreement with Nuka Enterprises

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) recently announced a new licensing agreement with Nuka Enterprises LLC to renew Nuka’s DehydraTECH™ license rights for use in its 1906 brand of cannabis chocolates. Nuka and 1906 have also acquired new rights in product categories in addition to the original chocolate formats, including candies, beverages, capsules and pills, and topical creams. “Nuka’s success with the 1906 brand of cannabis chocolates - recognized for their fast onset times, efficacy, taste and unique formulations – clearly demonstrate the market potential for DehydraTECH™. This comprehensive, long-term relationship between Nuka and Lexaria…

WednesdayApr 25, 2018 9:23 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Definitive License Agreement with GP Holdings LLC.

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has entered a definitive technology licensing agreement with California cannabis beverage manufacturer GP Holdings LLC. Per the agreement, the company will provide its patented DehydraTECH™ technology to enable next-generation performance in high absorption, fast acting cannabis infused beverages to be developed and sold in California. The agreement grants GP five-year semi-exclusive rights to use Lexaria's DehydraTECH™ technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on the products sold. In addition, GP has also acquired matching rights…

TuesdayApr 24, 2018 12:23 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Human Clinical Study of Its High Absorption TurboCBD Capsules

Study will measure the cardiovascular and cognitive health effects of patented DehydraTECH, its disruptive delivery technology Data generated will help company’s development of next-generation cannabinoid product formulations Chris Bunka, CEO, and John Docherty, president, to present at the ‘Next Generation Nicotine Delivery USA 2018’ conference in Atlanta on April 24 and 25 Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has started a human clinical study in Europe on the health effects of its high absorption TurboCBD™ capsules. LXRP, a drug delivery platform innovator, will be conducting the study to evaluate the cardiovascular and cognitive health effects of its patented DehydraTECH™…

MondayApr 23, 2018 9:29 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Initiates Human Clinical Study on TurboCBD Capsules; Presenting Breakthrough Nicotine Absorption Study Results

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has commenced a clinical study in Europe that is evaluating the cardiovascular and cognitive health effects of Lexaria's high absorption TurboCBD™ capsules. The data produced by the study will be of significant benefit to the company and its partners, providing objective human performance findings that will support the development of Lexaria’s next-generation cannabinoid product formulations. Results of the study are anticipated within 90 days. In addition, Lexaria also announced that it will be presenting the results of its recent breakthrough nicotine absorption study at…

WednesdayApr 18, 2018 11:32 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Significant Breakthrough with Alternative Nicotine Delivery Technology

Delivery technology already proven effective in cannabinoid delivery, now being studied in nicotine absorption Positive topline results on completion of first ingestible nicotine in vivo (animal) absorption study LXRP’s long-term strategy is to partner with leading firms in the tobacco industry, providing an additional layer of effectiveness in products to their already established consumer base Potential to revolutionize smokeless tobacco and the tobacco industry The drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced a significant breakthrough in alternative nicotine delivery technology. This cannabis-focused food bioscience company has a proprietary technology for improved delivery of bioactive…

TuesdayApr 17, 2018 11:10 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Topline Results from DehydraTECH™ Absorption Study

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced positive topline results following the completion of its first ingestible nicotine in vivo absorption study. The company is pursuing the use of its patented DehydraTECH™ technology as a new nicotine delivery method. The delivery method, in the form of an edible dose absorbed through the gastrointestinal tract, could potentially serve as a nicotine replacement therapy or as an alternative product format for regular tobacco users. Among other highlights, DehydraTECH™ demonstrated major nicotine absorption performance improvements including 1,160% faster delivery of equivalent peak quantities of nicotine to…

FridayApr 13, 2018 11:10 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patented Drug Delivery Portfolio with New Breakthroughs

Novel drug delivery system scientifically proven to increase absorption, bioavailability and efficacy New U.S. patents awarded, strengthening company’s IP portfolio Wide variety of patent families with ranging applications Building off DehydraTECH™, its patented lipophilic drug delivery platform, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has received another new Notice of Allowance from the United States Patent and Trademark Office that protects the company’s processes for making specific compositions of matter for enhanced cannabinoid delivery (http://ibn.fm/P1Q5a). This latest announcement comes on the heels of Lexaria’s March 22, 2018, press release that announced its receipt of a Notice of Allowance for the…

WednesdayApr 11, 2018 11:15 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Tech Promises Versatile Commercial Applications

DehydraTECH™ has been shown to improve the taste, smell, bioabsorption and bioavailability of high performance ingestible consumer products Lexaria is working to eliminate negative side effects and enhance the healthy benefits of a variety of bioactive compounds Research being conducted for healthier oral ingestion of vitamins, nicotine and opioids DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of active ingredients than traditional edibles. This technology is not a competing technology but rather a complementary layer that provides a versatile range…

WednesdayApr 11, 2018 10:04 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces New Notice of Allowance from US Patent and Trademark Office

Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has received another new Notice of Allowance from the United States Patent and Trademark Office providing claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology. This update comes on the heels of the company’s March 22, 2018, announcement of its reception of an additional Notice of Allowance for the compositions of matter. These two Notices of Allowance are expected to become Lexaria’s third and fourth granted patents in the United States. In recent months, Lexaria’s…

TuesdayApr 10, 2018 10:45 am

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Growing Patent Portfolio Enables Commercialization, Defense of DehydraTECH

LXRP recently received a new U.S. patent allowance for ‘composition of matter’ related to its DehydraTECH™ platform’s delivery of cannabinoids; based on past experience, company expects formal granting of patent within 100 days Company filed new U.S. patent application for use of DehydraTECH to improve the speed of absorption of active pharmaceutical ingredients through the skin; compared to other commercial formulations, LXRP product exhibited up to a 225 percent increase in permeability LXRP gets primary revenue through third party licensing fees related to its proprietary and patented intellectual property; goal is to partner with leading firms globally to deliver best-in-class…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP